CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
View/ Open
Date
2016-07Author
Lim, JSJ
Turner, NC
Yap, TA
Type
Journal Article
Metadata
Show full item recordAbstract
Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non-small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations. Cancer Discov; 6(7); 697-9. ©2016 AACRSee related article by Patnaik et al., p. 740.
Subject
Humans
Neoplasms
Breast Neoplasms
Aminopyridines
Benzimidazoles
Antineoplastic Agents
Treatment Outcome
Female
Male
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Clinical Trials as Topic
Research team
Molecular Oncology
Medicine Drug Development Unit (de Bono)
Language
eng
Date accepted
2016-05-03
License start date
2016-07
Citation
Cancer discovery, 2016, 6 (7), pp. 697 - 699